semaglutide and cardiovascular outcomes in patients with type 2 diabetes Oral Semaglutide and Cardiovascular Outcomes in
Description
A master pathway in metabolic therapy
a matched control group (excluding GLP1 costs), largely due to fewer inpatient admissions 2) There was a44% reduction in hospitalizations for major adverse cardiovascular events (MACE) including stroke, heart attack and heart failure in the first 24 months This research starts to quantify both the cost and the value side of the equation.
Semaglutide
Discover how our team fuels results and boosts confidence in your journey.
While these therapies reduce mortality and hospitalizations in HFrEF, their benefit in patients with heart failure with left ventricular ejection fraction (LVEF)40% remains less conclusive
Results The search strategy identified 833 hits, of which 42 studies were included in the final review
